Literature DB >> 9789825

The role of A beta 42 in Alzheimer's disease.

S G Younkin1.   

Abstract

Our recent studies of plasma, fibroblasts, transfected cells and transgenic mice show that a fundamental effect of the mutations linked to familial Alzheimer's disease (FAD) is to increase the extracellular concentration of A beta 42. This effect of the FAD-linked mutations is likely to be directly related to the pathogenesis of Alzheimer's disease (AD) because A beta 42 is deposited early and selectively in the senile plaques that are an invariant feature of all forms of AD. Thus our results provide strong evidence that the FAD-linked mutations all cause AD by increasing the extracellular concentration of A beta 42 (43), thereby fostering A beta deposition, and they support the hypothesis that cerebral A beta deposition is an essential early event in the pathogenesis of all forms of AD. Interactions between the basal forebrain cholinergic system and A beta that could influence AD pathogenesis are discussed.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9789825     DOI: 10.1016/s0928-4257(98)80035-1

Source DB:  PubMed          Journal:  J Physiol Paris        ISSN: 0928-4257


  100 in total

1.  Autocatalytic proteolysis of the transcription factor-coactivator C1 (HCF): a potential role for proteolytic regulation of coactivator function.

Authors:  J L Vogel; T M Kristie
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-15       Impact factor: 11.205

2.  Amyloid beta peptide load is correlated with increased beta-secretase activity in sporadic Alzheimer's disease patients.

Authors:  Rena Li; Kristina Lindholm; Li-Bang Yang; Xu Yue; Martin Citron; Riqiang Yan; Thomas Beach; Lucia Sue; Marwan Sabbagh; Huaibin Cai; Philip Wong; Donald Price; Yong Shen
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-20       Impact factor: 11.205

3.  Shifting a complex debate on γ-secretase cleavage and Alzheimer's disease.

Authors:  Todd E Golde; Yong Ran; Kevin M Felsenstein
Journal:  EMBO J       Date:  2012-04-13       Impact factor: 11.598

4.  Amyloid precursor protein and tau transgenic models of Alzheimer's disease: insights from the past and directions for the future.

Authors:  Naruhiko Sahara; Jada Lewis
Journal:  Future Neurol       Date:  2010-05-01

Review 5.  Inhibition of BACE1 for therapeutic use in Alzheimer's disease.

Authors:  Xiaoyang Luo; Riqiang Yan
Journal:  Int J Clin Exp Pathol       Date:  2010-07-08

6.  Aβ aggregation profiles and shifts in APP processing favor amyloidogenesis in canines.

Authors:  Viorela Pop; Elizabeth Head; Nicole C Berchtold; Charles G Glabe; Christa M Studzinski; Adam M Weidner; M Paul Murphy; Carl W Cotman
Journal:  Neurobiol Aging       Date:  2010-04-30       Impact factor: 4.673

Review 7.  Immune shaping and the development of Alzheimer's disease vaccines.

Authors:  Howard J Federoff; William J Bowers
Journal:  Sci Aging Knowledge Environ       Date:  2005-11-16

8.  A multigram chemical synthesis of the gamma-secretase inhibitor LY411575 and its diastereoisomers.

Authors:  Abdul H Fauq; Katherine Simpson; Ghulam M Maharvi; Todd Golde; Pritam Das
Journal:  Bioorg Med Chem Lett       Date:  2007-08-30       Impact factor: 2.823

Review 9.  The beta-secretase, BACE: a prime drug target for Alzheimer's disease.

Authors:  R Vassar
Journal:  J Mol Neurosci       Date:  2001-10       Impact factor: 3.444

Review 10.  Cellular prion protein mediates the toxicity of beta-amyloid oligomers: implications for Alzheimer disease.

Authors:  Haakon B Nygaard; Stephen M Strittmatter
Journal:  Arch Neurol       Date:  2009-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.